SOHM Inc. Welcomes Dr. Lucia Piccotti to Offer Expert Guidance on Cosmeceutical and Personal Health Product Research and Development
CHINO HILLS, CA / ACCESS Newswire / June 4, 2025 / SOHM, Inc. (OTC PINK:SHMN), a leading pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, health and wellness solutions, proudly announces the appointment of Dr. Lucia Piccotti, PhD, EMBA, as a key member of our team. Dr. Piccotti will serve on the advisory board, advising on the development of cutting-edge cosmeceuticals and personal health products utilizing SOHM's cutting-edge technological advancements.
Dr. Piccotti is a distinguished biomedical scientist and strategic business leader, bringing over a decade of expertise in blending scientific research with entrepreneurial innovation. Her career has taken her through pivotal roles in both Fortune 500 companies and dynamic biotech startups, where she has excelled in translating complex biomedical concepts into impactful consumer products and business strategies.
Most recently, Dr. Piccotti served as Senior Director of Strategic Innovation at Kiromic Biopharma, a biotechnology company at the forefront of cell therapies for cancer. Her contributions were instrumental in navigating the company's growth through the critical phases of pre-IPO and post-IPO operations. Notably, she led innovative initiatives that utilized exosome technologies for skin health, showcasing her extensive knowledge and versatility in both therapeutic and consumer health applications.
In addition to her role at Kiromic, Dr. Piccotti is the founder of Iguvia LLC, a consulting firm that specializes in cosmeceuticals and health products. Since 2018, she has directed multiple projects focused on phytoextract-based topical applications, drawing on her in-depth expertise in skin health and bioactive formulation.
Earlier in her career, Dr. Piccotti was a Lead Scientist at Kimberly-Clark Corporation, where she advanced biomedical research and product development in the personal care and cosmeceutical sectors. Her innovative work has resulted in numerous patents and industry-recognized advancements, particularly in the use of phytoextracts and topical formulations.
Dr. Piccotti's impressive track record includes managing cross-functional teams and complex research studies, as well as collaborating with various departments, including Marketing and Regulatory Affairs. Her extensive network within the medical community, including connections with top institutions like the University of Texas and MD Anderson Cancer Center, positions her uniquely to drive SOHM Inc.'s growth and innovation in the industry.
'With Dr. Piccotti on board, we are poised to elevate our approach to cosmeceuticals and personal health products,' said David Aguilar, COO of SOHM Inc. 'Her strategic thinking and innovative mindset will significantly enhance our capabilities and ensure we continue to deliver high-quality solutions that meet the evolving needs of consumers.'
Dr. Piccotti graduated with a PhD in Biochemistry, where her thesis focused on liposomal delivery of anionic phospholipids to support mitochondrial bioenergetics, with implications for cellular aging. She also holds an MS in Chemistry with a thesis in Synthetic Organic Chemistry, and an Executive MBA, demonstrating her commitment to both scientific excellence and business leadership. Her collaborative leadership style and entrepreneurial spirit will be invaluable as she helps SOHM navigate the complexities of the cosmeceutical market.
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted solutions for gene editing. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.
For further information regarding this announcement or to explore potential collaborations, please contact:
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: [email protected]
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains 'forward-looking statements,' which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
press release
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
an hour ago
- Los Angeles Times
Early-Stage Technology Disruptions and Trends Set to Define the Future of Business Systems
Researchers point to technologies addressing GenAI-enabled code architecture, disinformation security and surface asset management as the most likely to be widely adopted by businesses by 2030, while leaders find themselves reassessing cloud usage and not overlooking the ever-growing need for effective cybersecurity solutions Through its research and surveys of C-suiters, Gartner, Inc. has identified the most likely emerging technology disruptions that will impact businesses and define the future of business systems. Technology leaders are clearly prioritizing these over the next five years, as they present competitive opportunities in the near term and will eventually grow to become standard throughout businesses. 'Technology leaders must take action now to gain a first-mover advantage with these technologies,' said Bill Ray, distinguished VP analyst at Gartner. 'Innovative advancements like generative AI-enabled code architecture, disinformation security and Earth intelligence will provide the differentiation needed to help enterprises pull ahead of the pack in terms of data and product offerings.' Each disruptor is significant in its own right, but in combination, they start to define broader emerging solutions to new business practices. For example, advancing GenAI technologies will spawn new solutions around Earth intelligence and business simulation, spur the expansive growth of domainspecific language models and lead to higher functioning tools. GenAI solutions systems using free-form text and multimedia inputs/outputs will displace the conventional form-oriented sequential UI in established enterprise applications and enable new user scenarios. 'To remain competitive, traditional enterprise application software vendors will need to refactor applications to serve composable GenAI solutions that are invoked on demand via textual and multimodal prompts,' said Ray Valdes, VP analyst at Gartner. Because of this, Gartner predicts that by 2029, more than 50% of user interactions linked to enterprise business processes will leverage large language models to bypass the UI layer in traditional enterprise applications, up from less than 5% today. Disinformation security is an emerging discipline focused on threats from outside the corporate-controlled network. It includes a suite of technologies, such as deepfake detection, impersonation prevention and reputation protection, which can address disinformation to help enterprises discern trust, protect their brand and secure their online presence. Gartner predicts that by 2030, at least half of enterprises will have adopted products or services to address disinformation security, up from less than 5% in 2024. 'Disinformation attacks use external infrastructure, like social media, and originate from areas with limited legal oversight,' said Alfredo Ramirez IV, senior director analyst at Gartner. 'Tech leaders must add 'disinformation-proofing' to products by using AI/machine learning for content verification and data provenance tracking to help users discern the truth.' Gartner predicts that by 2028, 80% of major Earth surface assets globally will be monitored by active satellites. Earth intelligence tech uses AI to analyze satellite, aerial and ground data to monitor Earth's assets and activities, providing insights for decision-making. 'That doesn't mean maps and charts. Earth intelligence is delivering numbers on global nickel production, theme park revenue and the health of wheat crops, to name just a few,' said Ray. Given the breadth of applications, Earth intelligence is applicable to all industries and enterprises. Defense has been the first adopter, but improvements in the quality of data and analysis techniques have rapidly expanded the use cases. The Earth intelligence market is now divided between those who capture the data, those who interpret and analyze it and those who generate industry-specific insights. 'Earth intelligence applies to every business,' said Ray. 'Enterprises can gain an early advantage by creatively and strategically applying Earth intelligence to significantly enhance specific functionalities of existing systems or to compete via new net capabilities.' In a separate research report, Gartner has also announced the top trends shaping the future of cloud adoption over the next four years. These include cloud dissatisfaction, AI/machine learning (ML), multicloud, sustainability, digital sovereignty and industry solutions. Joe Rogus, director, advisory at Gartner, said, 'These trends are accelerating the shift in how cloud is transforming from a technology enabler to a business disruptor and necessity for most organizations. Over the next few years, cloud will continue to unlock new business models, competitive advantages and ways of achieving business missions.' Cloud adoption continues to grow, but not all implementations succeed. Gartner predicts 25% of organizations will have experienced significant dissatisfaction with their cloud adoption by 2028, due to unrealistic expectations, suboptimal implementation and/or uncontrolled costs. To remain competitive, enterprises need a clear cloud strategy and effective execution. Gartner research indicates that those who have successfully addressed upfront strategic focus by 2029 will find their cloud dissatisfaction will decrease. Gartner also predicts 50% of cloud computing resources will be devoted to AI workloads by 2029, up from less than 10% today. 'This all points to a fivefold increase in AI-related cloud workloads by 2029,' said Rogus. 'Now is the time for organizations to assess whether their data centers and cloud strategies are ready to handle this surge in AI and ML demand. In many cases, they might need to bring AI to where the data is to support this growth.' Many organizations that have adopted multicloud architecture find connecting to and between providers a challenge. This lack of interoperability between environments can slow cloud adoption, with Gartner predicting more than 50% of organizations will not get the expected results from their multicloud implementations by 2029. Gartner recommends identifying specific use cases and planning for distributed apps and data in the organization that could benefit from a cross-cloud deployment model. This enables workloads to operate collaboratively across different cloud platforms, as well as different onpremises and colocation facilities. AI adoption, tightening privacy regulations and geopolitical tensions are also driving demand for sovereign cloud services. Organizations will be increasingly required to protect data, infrastructure and critical workloads from control by external jurisdictions and foreign government access. Gartner predicts over 50% of multinational organizations will have digital sovereign strategies by 2029, up from less than 10% today. 'As organizations proactively align their cloud strategies to address digital sovereignty requirements, there are already a wide range of offerings that will support them,' said Rogus. 'However, it's important they understand exactly what their requirements are, so they can select the right mix of solutions to safeguard their data and operational integrity.' With all the talk of businesses onboarding GenAI and other emerging technology solutions, it's easy to overlook cybersecurity tools. CEOs, however, are not forgetting to lock the proverbial door. Gartner's research has shown that a whopping 85% of CEOs surveyed say that cybersecurity is critical for business growth moving forward. In a survey of 456 CEOs and other senior business executives, 61% of CEOs are concerned about cybersecurity threats, driven in large part by AI's growing role in commercial activity and the political debates about the sourcing and use of advanced technologies. As risk thresholds shift, they view cybersecurity as a key driver. 'Cybersecurity is no longer just about protection; it's a critical driver for business growth,' said David Furlonger, distinguished vice president analyst and Gartner fellow. 'With 85% of CEOs recognizing its importance, security leaders have a unique opportunity to demonstrate the value of cybersecurity investments not only in safeguarding assets but also in enabling strategic business objectives.' 'Effective communication is key,' said Furlonger. 'CEOs should highlight the role of security leaders in both protecting the business and enhancing cybersecurity to drive growth. This involves, for example, assessing risks in foreign markets and intellectual property protection. Security leaders are positioned to significantly influence value generation, and they should communicate how cybersecurity aids enterprise growth.' With regulatory changes and cybersecurity threats challenging competitiveness, CEOs said they see a direct linkage between cybersecurity capabilities and enterprise growth. Meanwhile, C-suiters' comfort level with AI is far from established at this point. Only 44% of CIOs are deemed by their CEOs to be 'AI-savvy' according to the Gartner data. The survey revealed that 77% of CEOs believe that AI is indeed ushering in a new business era, yet they feel their organization's leading technology experts lack the knowledge and capabilities to support, drive or accelerate business outcomes in this evolving landscape. 'We have never seen such a disproportionate gap in CEOs' impressions about technological disruption,' said Furlonger. 'AI is not just an incremental change from digital business. AI is a step change in how business and society work. A significant implication is that if savviness across the C-suite is not rapidly improved, competitiveness will suffer and corporate survival will be at stake.' CEOs perceive even the CIO, chief information security officer (CISO) and chief data officer (CDO) as lacking AI savviness. CEOs highlighted that the top two limiting factors impacting AI's deployment and use are the inability to hire adequate numbers of skilled people and an inability to calculate value or outcomes. 'CEOs have shifted their view of AI from just a tool to a transformative way of working,' said Jennifer Carter, principal analyst at Gartner. 'This change has highlighted the importance of upskilling. As leaders recognize AI's potential and its impact on their organizations, they understand that success isn't just about hiring new talent. Instead, it's about equipping their current employees with the skills needed to seamlessly incorporate AI into everyday tasks.'
Associated Press
11 hours ago
- Associated Press
Does Hospital Indemnity Insurance Help Cover Recurring Stays?
NEW YORK, NY / ACCESS Newswire / June 21, 2025 / A three-day stay in the hospital costs an average of $30,000 in the United States.1 While health insurance can help reduce your out-of-pocket costs if you have to be admitted to the hospital, there are contingent costs that may not be covered by your insurer. The cost of hospital stays, and other expenses like childcare could have a significant impact while you are unable to work. A hospital indemnity insurance policy can help with these costs. Here, we explore what health insurance helps cover and how the cash benefits of hospital indemnity insurance can help fill coverage gaps relating to recurring hospital stays. What does health insurance help cover? Many people receive health insurance through their employer, which can help with the cost of a hospital stay. Employer-sponsored health insurance plans cost an average of $111 per month, while Marketplace plans cost an average of $456 per month.2 So, if you're wondering, " How much is health insurance ?,' the answer depends on your specific circumstances and plan options. Marketplace health insurance plans typically cover a range of essential health benefits, including:3 Outpatient services Emergency services Hospitalization for surgery or overnight stays Pregnancy, maternity and newborn care Mental health and behavioral health treatment Prescription drugs Rehabilitative and habilitative services and devices Laboratory services Preventive and wellness services Chronic disease management Pediatric services Hospital costs are usually covered at least in part by primary health insurance plans, but you'll still have to pay copays and deductibles, and your health insurance plan may be subject to coverage limits. What is hospital indemnity insurance? Hospital indemnity insurance is a supplemental plan that can help fill gaps in your primary health insurance. It's not a replacement for health insurance but can help you with unexpected expenses and provide additional support if you've had multiple hospital stays that forced you to reach a coverage limit. Hospital indemnity insurance works similarly to health insurance in that you pay premiums to an insurance provider in exchange for coverage. You may have access to a plan through your employer, or you can purchase an individual plan directly from an insurance company. Unlike health insurance, however, hospital indemnity insurance plans typically pay eligible cash benefits based on the policy option you choose. You can use the benefits in any way you see fit, such as: Out-of-pocket medical expenses Childcare Living expenses like groceries, rent and utilities Plans may function differently between providers, but typically, you can file a claim for care provided while in the hospital, and your insurance provider pays eligible claims to help you with the costs of your hospital stay. Why is hospital indemnity insurance worth it? There are a number of reasons why you might consider a hospital indemnity insurance plan. These may include: Added financial assistance: Hospital stays can be expensive, especially if you have to go multiple times in the same year. Hospital indemnity insurance helps provide added financial support for recurring visits. Flexibility: Health insurance plans typically pay the hospital directly for treatment. But hospital indemnity insurance pays cash benefits direct to the policyholder, unless otherwise assigned, so you can use it for both medical and non-medical costs. Surpassing coverage limits: If you've reached a health insurance coverage limit after being admitted to the hospital several times, you could still use the hospital indemnity insurance. Ultimately, if you think you or a family member will have multiple stays at the hospital in a given year, hospital indemnity insurance could help provide some added peace of mind. The bottom line Hospital indemnity insurance provides coverage options that can help with recurring hospital stays. This supplemental policy pays cash benefits direct to the policyholder, unless otherwise assigned, so you can use your benefits to help fill gaps in your health insurance coverage or help pay living expenses. Consider applying for a hospital indemnity insurance policy for added peace of mind. Sources: 1 - Why health insurance is important. Accessed May 12, 2025. 2 Ramsey Solutions - How Much Does Health Insurance Cost? Updated May 12, 2025. Accessed May 12, 2025. 3 - Health benefits & coverage. Accessed May 12, 2025. Content within this article is provided for general informational purposes and is not provided as tax, legal, health, or financial advice for any person or for any specific situation. Employers, employees, and other individuals should contact their own advisers about their situations. For complete details, including availability and costs of Aflac insurance, please contact your local Aflac agent. Aflac coverage is underwritten by American Family Life Assurance Company of Columbus. In New York, Aflac coverage is underwritten by American Family Life Assurance Company of New York. Hospital, B40000 series: In Delaware, Policies B40100DE & B4010HDE. In Idaho, Policies B40100ID & B4010HID. In Oklahoma, Policies B40100OK & B4010HOK. In Pennsylvania, Policies B40100PA & B4010HPA. In Virginia, Policies B40100VA & B4010HVA. Coverage may not be available in all states, including but not limited to DE, ID, NJ, NM, NY, VA or VT. Benefits/premium rates may vary based on state and plan levels. Optional riders may be available at an additional cost. Policies and riders may also contain a waiting period. Refer to the exact policy and rider forms for benefit details, definitions, limitations, and exclusions. Aflac WWHQ | 1932 Wynnton Road | Columbus, GA 31999 CONTACT: Senior PR & Corporate Communications Contact: Angie Blackmar, 706-392-2097 or [email protected] SOURCE: Aflac press release
Business Upturn
13 hours ago
- Business Upturn
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, June 21, 2025 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, both dates inclusive (the 'Class Period'), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc. , No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI and certain of Tempus AI's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Tempus AI class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence, including generative AI. The Tempus AI class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Tempus AI inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (ii) the credibility and substance of Tempus AI's joint venture with SoftBank Group Corporation was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus AI; (iii) Tempus AI-acquired Ambry Genetics Corporation had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (iv) AstraZeneca PLC had reduced its financial commitments to Tempus AI through a questionable 'pass-through payment' via a joint agreement between it, Tempus AI, and Pathos AI, Inc.; and (v) the above issues revealed weakness in core operations and revenue prospects. The Tempus AI class action lawsuit further alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued research report on Tempus AI that raised numerous red flags over Tempus AI's management, operations, and financial reporting. On this news, the price of Tempus AI stock fell more than 19%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Tempus AI common stock during the Class Period to seek appointment as lead plaintiff in the Tempus AI class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Tempus AI class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Tempus AI class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Tempus AI class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
